Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:NWBO

Northwest Biotherapeutics Q1 2025 Earnings Results & Report

Northwest Biotherapeutics logo
$0.17 +0.00 (+0.96%)
As of 11/11/2026 03:55 PM Eastern

Northwest Biotherapeutics reported Q1 2025 earnings on May 15, 2025. The company reported EPS of -$0.01, while revenue was $380 thousand.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
After Market Closes

Northwest Biotherapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Northwest Biotherapeutics Revenue Results

Actual Revenue
$380 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Northwest Biotherapeutics' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Northwest Biotherapeutics Q1 2025 Earnings FAQ

Northwest Biotherapeutics (OTCMKTS:NWBO) reported earnings of -$0.01 per share for Q1 2025. The report was announced on Thursday, May 15, 2025.

Northwest Biotherapeutics reported revenue of $380 thousand for Q1 2025.

Northwest Biotherapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Northwest Biotherapeutics on the company's earnings history page.

Northwest Biotherapeutics Earnings Headlines

Northwest Biotherapeutics Announces Expansion of Its Technical Team
October 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-expansion-of-its-technical-team-302919492.html
Northwest Biotherapeutics announces NHSBT collaboration to support DCVax-L production in the UK
October 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/northwest-biotherapeutics-announces-nhsbt-collaboration-to-support-dcvax-l-production-in-the-uk/ar-AA2dTtn4
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
 |  Weiss Ratings (Ad)
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
October 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-the-uk-national-health-service-blood-and-transplant-announce-collaboration-to-support-dcvax-l-production-302903002.html
Northwest Biotherapeutics highlights personalized cancer vaccine approach at NHS oncology conference
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/northwest-biotherapeutics-highlights-personalized-cancer-vaccine-approach-at-nhs-oncology-conference/ar-AA2dGVTW
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual ...
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/northwest-biotherapeutics-announces-keynote-presentation-070000164.html
See More Northwest Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Northwest Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Northwest Biotherapeutics and other key companies, straight to your email.

About Northwest Biotherapeutics

Northwest Biotherapeutics (OTCMKTS:NWBO) is a biotechnology company developing immunotherapies for cancer, with a focus on treatments made from a patient’s own immune cells. Its platform uses dendritic cells, which can help the immune system recognize and respond to cancer.

The company’s lead product candidate, DCVax-L, is a personalized dendritic-cell therapy being developed for glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational therapy designed to be injected into tumors. These candidates are not established treatments, and their development is subject to clinical and regulatory review.

Northwest Biotherapeutics is headquartered in the United States and has manufacturing operations in the United Kingdom. Its work has included clinical research in multiple countries.

View Northwest Biotherapeutics Profile
Earnings Tools